What is Climb Bio, Inc.'s G&A?

Climb Bio, Inc. (CLYM) reported G&A of $5.84M in Q1 2026.

How has Climb Bio, Inc.'s G&A changed year-over-year?

Climb Bio, Inc.'s G&A increased by 2.6% year-over-year, from $5.69M to $5.84M.

What is the long-term trend for Climb Bio, Inc.'s G&A?

Over 4 years (2021 to 2025), Climb Bio, Inc.'s G&A has grown at a 14.4% compound annual growth rate (CAGR), from $12.35M to $21.17M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Climb Bio, Inc. CLYM G&A

G&A at other companies

Vera TherapeuticsVERA

$39.12M+146%

Kyverna Therapeutics, Inc.KYTX

$11.29M+13.2%

Cullinan Therapeutics, Inc.CGEM

$11.57M-14.5%

Jade Biosciences, Inc. Common StockJBIO

$7.39M+120%

Shattuck Labs, Inc.STTK

$4.6M+2.9%

Artiva Biotherapeutics, Inc.ARTV

$5.12M0.0%

Other financials

Income statement

See full

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Balance sheet

See full

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Cash flow

See full

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Valuation

See full

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Returns & leverage

See full

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Climb Bio, Inc.'s G&A?: Climb Bio, Inc. (CLYM) reported G&A of $5.84M in Q1 2026.
How has Climb Bio, Inc.'s G&A changed year-over-year?: Climb Bio, Inc.'s G&A increased by 2.6% year-over-year, from $5.69M to $5.84M.
What is the long-term trend for Climb Bio, Inc.'s G&A?: Over 4 years (2021 to 2025), Climb Bio, Inc.'s G&A has grown at a 14.4% compound annual growth rate (CAGR), from $12.35M to $21.17M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.